The new software is designed to help healthcare professionals treat sleep disorders.
Medical sleep technology company Vivos Therapeutics, Inc. has announced the release of its AireO2TM software. The new patient management software technology is designed to help healthcare professionals diagnose, treat, and monitor patients with obstructive sleep apnea (OSA) more effectively.
Patients with untreated OSA are at greater risk of comorbidities such as hypertension, heart failure, stroke, and other conditions, according to a press release from Vivos. The AireO2 features enhancements that are said to help healthcare professionals with billing services and more, including practice management systems. The software was developed in collaboration with Lyon Dental.
“We believe that Vivos’ sleep-specific AireO2 patient management technology represents a significant advancement in how medical and dental professionals will be able to treat sleep disorders,” said Kirk Huntsman, Vivos’ Chairman and CEO. “Sleep apnea is a serious chronic disease that impacts much more than just sleep – it impacts patients’ quality of life and overall health. With AireO2, we believe that we can make it significantly easier for sleep disorder healthcare providers to manage their growing caseloads and increase the number of patients whom they can treat on any given day. We look forward to continuing the launch of AireO2 as a complement to our existing Billing Intelligence Service for our Vivos Integrated Practices and to actively pursuing AireO2 as a revenue source from other OSA-focused healthcare providers.”
Based in Highlands Ranch, Colorado, Vivos Therapeutics is a medical technology company that is focused on developing treatments for patients suffering from sleep-disordered breathing. The Vivos System is reportedly the first non-surgical, non-invasive, non-pharmaceutical solution for patients with OSA. For more information, visit vivoslife.com.